Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Trading 06-11 11:11:50 EDT

1.95

+0.08

+4.13%

High1.95	Low1.82	Vol474.06K
Open1.91	D1 Closing1.87	Amplitude6.81%
Mkt Cap226.40M	Tradable Cap196.28M	Total Shares116.26M
T/O897.40K	T/O Rate0.47%	Tradable Shares100.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":1.9473,"timestamp":1781190704450,"preClose":1.87,"halted":0,"volume":474059,"delay":0,"changeRate":0.04133689839572188,"floatShares":100797117,"shares":116263459,"eps":-1.089789,"marketStatus":"Trading","change":0.0773,"latestTime":"06-11 11:11:50 EDT","open":1.91,"high":1.9473,"low":1.82,"amount":897402.694121,"amplitude":0.068075,"askPrice":1.95,"askSize":709,"bidPrice":1.94,"bidSize":2843,"shortable":3,"etf":0,"ttmEps":-1.089789,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781208000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":1.87,"preHourTrading":{"tag":"盘前","latestPrice":1.928,"preClose":1.87,"latestTime":"09:04 EDT","volume":6301,"amount":12138.6326513,"timestamp":1781183051992,"change":0.058,"changeRate":0.031016,"amplitude":0.069144},"postHourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":1.87,"latestTime":"19:31 EDT","volume":37040,"amount":69829.1903,"timestamp":1781134306301,"change":0.08,"changeRate":0.042781,"amplitude":0.080107},"volumeRatio":0.708537,"impliedVol":0.9362,"impliedVolPercentile":0.3506},"requestUrl":"/m/hq/s/FATE/tweets","defaultTab":"tweets","newsList":[{"id":"2642628154","title":"Piper Sandler Remains a Buy on Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642628154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642628154?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:18","pubTimestamp":1781003890,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Fate Therapeutics today and set a price target of $6.00. Tenthoff covers the Healt...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-fate-therapeutics-fate-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-fate-therapeutics-fate-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641485788","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2641485788","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641485788?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:30","pubTimestamp":1780914611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fate Therapeutics (FATE), Atai Beckley N.V. (ATAI) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-210?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-210?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","ATAI","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641548598","title":"Fate Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2641548598","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641548598?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:30","pubTimestamp":1780914600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FATE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 06:30 ET (10:30 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641144532","title":"Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641144532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641144532?lang=en_us&edition=fundamental","pubTime":"2026-06-06 01:21","pubTimestamp":1780680104,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-united-therapeutics-uthr-fate-therapeutics-fate-and-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-united-therapeutics-uthr-fate-therapeutics-fate-and-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1571399168.USD","BK4007","HCSG","BK4588","XBI","BK4532","BK4137","LU1699723380.USD","BK4585","LU0128526141.USD","BK4539","LU0029874061.USD","UTHR","FATE","LABU","BK4139","XLV","EWTX","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641316078","title":"Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2641316078","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641316078?lang=en_us&edition=fundamental","pubTime":"2026-06-05 06:18","pubTimestamp":1780611497,"startTime":"0","endTime":"0","summary":"Fate Therapeutics ( ($FATE) ) has shared an announcement. On June 4, 2026, Fate Therapeutics updated its corporate presentation ahead of investor a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-advances-off-the-shelf-car-t-autoimmune-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-advances-off-the-shelf-car-t-autoimmune-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4022","BK4230","FATE","CAR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641161797","title":"Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability","url":"https://stock-news.laohu8.com/highlight/detail?id=2641161797","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641161797?lang=en_us&edition=fundamental","pubTime":"2026-06-05 02:25","pubTimestamp":1780597529,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating on May 21. Gil Blum has given his Hold rating due ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/gil-blum-reiterates-hold-on-fate-therapeutics-as-early-ft819-data-show-promise-but-uncertain-durability-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/gil-blum-reiterates-hold-on-fate-therapeutics-as-early-ft819-data-show-promise-but-uncertain-durability-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640815729","title":"Fate Therapeutics reports Phase 1 data for FT819 CAR-T in lupus with reduced conditioning regimen","url":"https://stock-news.laohu8.com/highlight/detail?id=2640815729","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640815729?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:33","pubTimestamp":1780576418,"startTime":"0","endTime":"0","summary":"Fate Therapeutics presented Phase 1 data at EULAR on FT819, an off-the-shelf anti-CD19 CAR T-cell therapy for systemic lupus erythematosus.Results showed rapid, sustained clinical improvement with a favorable tolerability profile under reduced-intensity conditioning, supporting outpatient, same-day discharge use.Findings also indicated durable B-cell depletion with a reset toward a healthier B-cell repertoire while preserving existing vaccine-derived immunity.The readout supported bendamustine as the preferred conditioning approach for RECLAIM-LN, a planned Phase 2 potentially registrational trial in lupus nephritis.Separate preclinical data presented for FT839 suggested broad elimination of disease-driving immune cells in rheumatoid arthritis samples without preconditioning, positioning a next-generation autoimmune program.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7qVx4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4139","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4112","BK4588","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","FATE","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157248","title":"Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157248","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157248?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:30","pubTimestamp":1780576200,"startTime":"0","endTime":"0","summary":"FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306754/24675/en/Fate-Therapeutics-Showcases-Data-from-FT819-and-FT839-Programs-at-the-European-Congress-of-Rheumatology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","BK4077","IE00B66KJ199.SGD","CRS","EPV","FATE","IE0031619046.USD","IE00B7SZL793.SGD","LU0963586101.USD","BK4022","LU2065731478.USD","BK4230","SLE","BK4139","IE00B19Z4B17.USD","BK4006","BK4187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640184273","title":"Fate Therapeutics management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2640184273","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640184273?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:55","pubTimestamp":1780520138,"startTime":"0","endTime":"0","summary":"Meeting to be held on June 8 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640234059","title":"Fate Therapeutics grants 67,300 RSUs to two new hires under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2640234059","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640234059?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430724,"startTime":"0","endTime":"0","summary":"Fate Therapeutics granted RSUs covering 67,300 common shares to two newly hired non-executive employees on June 1, 2026.Awards were issued under the Amended and Restated Inducement Equity Plan.RSUs vest over four years, with 25% vesting on each anniversary of the grant date, subject to continued employment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLbhyvV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BN0W2W23.USD","FATE","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BK4139","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","BK4112","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640234659","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640234659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640234659?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUADR0BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640492378","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640492378","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640492378?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, June  02, 2026  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305584/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640095144","title":"Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo","url":"https://stock-news.laohu8.com/highlight/detail?id=2640095144","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640095144?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:33","pubTimestamp":1780317218,"startTime":"0","endTime":"0","summary":"Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo. Fate Therapeutics presented preliminary Phase 1 data for off-the-shelf CAR T-cell candidate FT836 at the 2026 ASCO annual meeting.Early results showed tumor shrinkage signals in heavily pre-treated KRAS wild-type metastatic colorectal cancer without conditioning chemotherapy.Safety profile appeared favorable, with no severe immune-related toxicities reported in the initial patient set.Drug cells were detected in blood and later in tumor tissue, supporting trafficking and functional persistence without lymphodepletion.Company signaled a strategic focus on KRAS wild-type colorectal cancer as enrollment continues.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLb9BMwB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0314104364.USD","FATE","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4112","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4588","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951213","title":"Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951213","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951213?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317000,"startTime":"0","endTime":"0","summary":"FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illus","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304368/24675/en/Fate-Therapeutics-Showcases-Clinical-Data-for-FT836-at-the-American-Society-of-Cancer-Oncology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638054452","title":"Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638054452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638054452?lang=en_us&edition=fundamental","pubTime":"2026-05-27 01:50","pubTimestamp":1779817812,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zevra-therapeutics-zvra-fate-therapeutics-fate-and-mirum-pharmaceuticals-mirm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zevra-therapeutics-zvra-fate-therapeutics-fate-and-mirum-pharmaceuticals-mirm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XBI","XLV","ZVRA","LU0128526141.USD","HCSG","MIRM","BK4585","BK4588","LABU","FATE","LU0029874061.USD","BK4137","BK4581","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637321435","title":"CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2637321435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637321435?lang=en_us&edition=fundamental","pubTime":"2026-05-23 17:01","pubTimestamp":1779526878,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($CTXR) ), ( ($AMT) ), ( ($JAZZ) ), ( ($CTMX) ) and ( ($FATE) ). Here is a breakdown of their recent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/ctxr-amt-jazz-ctmx-fate-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/ctxr-amt-jazz-ctmx-fate-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMT","BK4533","BK4588","LU0320765992.SGD","JAZZ","BK4139","IE00BN0W2W23.USD","LU0154245673.USD","BK4084","BK4007","IE00BN0W2T93.GBP","LU0889565916.HKD","LU0823416689.USD","BK4534","BK4585","BK4581","BK4554","BK4532","IE00BN0W2V16.EUR","CTMX","FATE","BK4219","LU0154245756.USD","CTXR","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637361095","title":"Top Fate Therapeutics Insiders Quietly Unload Shares in Back‑to‑Back Moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2637361095","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637361095?lang=en_us&edition=fundamental","pubTime":"2026-05-22 10:11","pubTimestamp":1779415906,"startTime":"0","endTime":"0","summary":"New insider activity at Fate Therapeutics ( ($FATE) ) has taken place on May 21, 2026. Key insiders at Fate Therapeutics have recently unloaded not...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-fate-therapeutics-insiders-quietly-unload-shares-in-back‑to‑back-moves-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-fate-therapeutics-insiders-quietly-unload-shares-in-back‑to‑back-moves-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637335423","title":"Fate Therapeutics Announces Presentations at 2026 Asco and Eular Annual Meetings Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2637335423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637335423?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:30","pubTimestamp":1779366600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA4VCHQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637335005","title":"Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2637335005","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637335005?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:30","pubTimestamp":1779366600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  21, 2026  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299320/24675/en/Fate-Therapeutics-Announces-Presentations-at-2026-ASCO-and-EULAR-Annual-Meetings-Highlighting-Off-the-Shelf-CAR-T-cell-Therapy-Pipeline-for-Cancer-and-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4230","CAR","FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636869410","title":"Fate Therapeutics assumed with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2636869410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636869410?lang=en_us&edition=fundamental","pubTime":"2026-05-20 03:15","pubTimestamp":1779218109,"startTime":"0","endTime":"0","summary":"Jefferies assumed coverage of Fate Therapeutics (FATE) with a Buy rating and $4 price target Lead program FAT819 is in Phase 1 for various autoimmu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-assumed-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-assumed-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DBB","FATE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1577},{"period":"1month","weight":-0.1422},{"period":"3month","weight":0.5983},{"period":"6month","weight":0.6261},{"period":"1year","weight":0.1198},{"period":"ytd","weight":0.9031}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0188},{"period":"3month","weight":0.0891},{"period":"6month","weight":0.0641},{"period":"1year","weight":0.2029},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.615385,"avgChangeRate":0.004138},{"month":5,"riseRate":0.461538,"avgChangeRate":0.079338},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.023314},{"month":7,"riseRate":0.416667,"avgChangeRate":0.050198},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.024603},{"month":9,"riseRate":0.416667,"avgChangeRate":0.00072},{"month":10,"riseRate":0.25,"avgChangeRate":-0.091603},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}